Oxford Technology Management

OrganOx Limited, founded in 2008 and based in Oxford, United Kingdom, specializes in organ preservation and transplantation technology, particularly for liver transplants. The company has developed the Metra device, which employs normothermic preservation technology to store livers outside the body at normal body temperature. This innovative approach mimics the conditions of the human body by continuously perfusing the liver with oxygen-carrying red cells and nutrients, thereby preventing the decay of the organ before transplantation. The Metra device enables the liver to produce bile, metabolize glucose, and maintain a physiological pH level, ultimately enhancing the viability of the organ for transplant. OrganOx's research and development efforts are rooted in the work of Prof Peter Friend and Prof Constantin Coussios at the University of Oxford.

Metacarpal specializes in the development of innovative bionic prosthetic hands designed to enhance the quality of life for individuals with limb differences. Their pioneering technology features fully mechanical prostheses capable of variable grips, allowing users to effortlessly switch between different hand positions for various tasks. This adaptability ensures a secure grip on objects of varying shapes and sizes, complemented by a grip lock feature for added stability. By integrating intuitive control mechanisms reminiscent of body-powered devices, Metacarpal aims to provide users with a natural and responsive experience. In addition to serving individuals in developed regions, the company is committed to supplying prosthetics to underprivileged communities in the developing world, addressing a critical need for accessible assistive technology.

CryoLogyx is an early-stage biotechnology company focused on advancing cell cryopreservation technology to enhance drug discovery processes. By employing innovative methods that utilize cryoprotectants, CryoLogyx transforms the freezing, storage, and transportation of cells. This proprietary technology ensures the delivery of viable, ready-to-use cells and cell therapies, allowing healthcare researchers to access these resources in the desired format. The company's approach aims to improve the efficiency and effectiveness of cell-based research in the fields of medicine discovery, diagnostics, and cell therapy.

MitoRx Therapeutics is a biotechnology company that focuses on developing innovative therapeutics aimed at reversing mitochondrial dysfunction. The company targets various conditions, including neuromuscular disorders, metabolic diseases, and dementia. By specializing in mitochondrial-protective therapies, MitoRx seeks to address the underlying causes of these challenging diseases. The company is committed to both developing treatments for rare indications and forming partnerships to tackle broader health issues. Through its efforts, MitoRx aims to enable healthcare professionals to halt the progression of conditions associated with dystrophy and neurodegeneration.

OxCan is a startup focused on early lung cancer detection using machine learning and liquid biopsy techniques. The company has developed an artificial intelligence-based healthcare platform that identifies cancer through targeted blood testing. This platform effectively detects cancer-related materials released into the bloodstream, allowing for cost-effective and routine analysis. It evaluates multidimensional liquid biopsy results, including DNA, proteins, epigenetic factors, as well as incorporating epidemiological data and patient medical histories. By providing healthcare providers with the tools for early cancer detection, OxCan aims to facilitate timely and potentially curative treatment options.

MitoRx Therapeutics is a biotechnology company that focuses on developing innovative therapeutics aimed at reversing mitochondrial dysfunction. The company targets various conditions, including neuromuscular disorders, metabolic diseases, and dementia. By specializing in mitochondrial-protective therapies, MitoRx seeks to address the underlying causes of these challenging diseases. The company is committed to both developing treatments for rare indications and forming partnerships to tackle broader health issues. Through its efforts, MitoRx aims to enable healthcare professionals to halt the progression of conditions associated with dystrophy and neurodegeneration.

OxCan is a startup focused on early lung cancer detection using machine learning and liquid biopsy techniques. The company has developed an artificial intelligence-based healthcare platform that identifies cancer through targeted blood testing. This platform effectively detects cancer-related materials released into the bloodstream, allowing for cost-effective and routine analysis. It evaluates multidimensional liquid biopsy results, including DNA, proteins, epigenetic factors, as well as incorporating epidemiological data and patient medical histories. By providing healthcare providers with the tools for early cancer detection, OxCan aims to facilitate timely and potentially curative treatment options.

Machine Discovery is a spin-out from the University of Oxford focused on commercializing advanced machine learning technology. The company has developed a simulation management platform that utilizes proprietary neural network technology to enhance the efficiency of compute-intensive tasks. This platform enables clients to conduct simulations with minimal data input while achieving a high level of accuracy, specifically 99.9% fidelity. By accelerating costly calculations, Machine Discovery provides valuable statistical insights that aid clients in speeding up their innovation processes, thus addressing critical demands in various sectors.

Lightpoint Medical, Ltd. is a medical device company based in Rickmansworth, United Kingdom, founded in 2012. The company specializes in developing innovative imaging technologies for cancer surgery, particularly through its Cerenkov Luminescence Imaging (CLI) technology. This breakthrough intraoperative imaging tool allows for real-time detection of cancer during surgical procedures, which can significantly reduce the chances of cancer recurrence and the necessity for reoperations. By optimizing the performance of robotic cancer surgery, Lightpoint Medical aims to provide healthcare professionals with advanced tools that enhance surgical decision-making and improve patient outcomes, ultimately contributing to cost savings within the healthcare system.

GripAble Ltd. designs and develops digital therapy devices aimed at improving rehabilitation for individuals with movement impairments such as stroke, arthritis, cerebral palsy, and trauma. Founded in 2017 and based in London, the company offers a portable, wireless handgrip device that connects to a mobile application. This application allows users to engage with therapy games while providing assessment and training for hand and arm functions. GripAble's innovative approach focuses on making therapy more accessible and engaging for patients, enabling them to practice essential daily tasks in a fun and motivating way. By combining hardware and software, GripAble addresses the needs of over 500 million people worldwide who face challenges with arm mobility, facilitating self-training both in clinical settings and at home.

Oxwash is a provider of sustainable on-demand laundry and dry cleaning services based in Oxford, United Kingdom. Founded by Dr. Kent Grant in 2018, the company focuses on offering eco-friendly solutions through a logistics system that employs electric cargo bikes and a fleet of electric vehicles. Oxwash is committed to achieving clinically clean results while ensuring net zero carbon emissions throughout its operations, from collection to washing and delivery. By developing environmentally responsible processes, the company enables customers to access laundry services that align with their sustainability goals.

Curileum Discovery Ltd, based in London, is a biotechnology company focused on developing innovative therapeutic solutions for gastrointestinal diseases. Established in 2013, the company is engaged in discovering novel treatments to address early-stage severe gastrointestinal conditions. One of its key developments, ULI-015, is a small molecule designed to redirect the production of precancerous cells in polyps to healthy tissue. In preclinical studies using a porcine bowel cancer model, ULI-015 demonstrated significant efficacy, leading to a reduction in polyp numbers and promoting the fusion of regressed polyps with healthy tissue. Curileum has also established a large-scale method to extract ULI-015 from plant sources and is pursuing Orphan Drug Designation to initiate clinical testing in patients with familial adenomatous polyposis. Positioned at St Mark’s Hospital, which houses Europe’s largest registry of FAP patients, Curileum aims to address the sporadic bowel cancer market by targeting high-risk individuals identified through screening programs. The company is currently seeking funding to advance ULI-015 towards clinical proof of concept.

Atelerix Limited, based in Cambridge, United Kingdom, specializes in the storage and transportation of viable cells and tissues at room temperature. Founded in 2006, the company has developed a patented technology that utilizes alginate hydrogels to encapsulate biological products, protecting them from biochemical and physical damage during storage and shipping. This innovative approach eliminates the need for cryopreservation, making it easier for customers to use cells and assays immediately upon arrival without the risk of cytotoxicity or damage. Atelerix's technology enhances predictability and reliability in drug discovery models and cell therapies, allowing for the safe storage and transport of suspended and planted cells, as well as tissues and stem cells.

Lightpoint Medical, Ltd. is a medical device company based in Rickmansworth, United Kingdom, founded in 2012. The company specializes in developing innovative imaging technologies for cancer surgery, particularly through its Cerenkov Luminescence Imaging (CLI) technology. This breakthrough intraoperative imaging tool allows for real-time detection of cancer during surgical procedures, which can significantly reduce the chances of cancer recurrence and the necessity for reoperations. By optimizing the performance of robotic cancer surgery, Lightpoint Medical aims to provide healthcare professionals with advanced tools that enhance surgical decision-making and improve patient outcomes, ultimately contributing to cost savings within the healthcare system.

Atelerix Limited, based in Cambridge, United Kingdom, specializes in the storage and transportation of viable cells and tissues at room temperature. Founded in 2006, the company has developed a patented technology that utilizes alginate hydrogels to encapsulate biological products, protecting them from biochemical and physical damage during storage and shipping. This innovative approach eliminates the need for cryopreservation, making it easier for customers to use cells and assays immediately upon arrival without the risk of cytotoxicity or damage. Atelerix's technology enhances predictability and reliability in drug discovery models and cell therapies, allowing for the safe storage and transport of suspended and planted cells, as well as tissues and stem cells.

Molecular Warehouse Ltd., incorporated in 2015 and based in Twickenham, United Kingdom, specializes in developing proteins for diagnostics and therapeutics. The company focuses on creating patient-centric biosensor technology that enhances molecular diagnostics. Their innovative electrochemical biosensors are designed to detect a variety of biomarkers with high specificity and sensitivity, allowing for rapid health monitoring. This technology enables patients to conduct regular health assessments from home and facilitates seamless communication of test results with healthcare providers through smart devices.

Bodle Technologies Limited specializes in advanced optoelectronic solutions, focusing on innovative display technologies and smart window applications. The company has developed the world's first solid-state reflective display technology, SRD®, which utilizes phase-change materials to deliver vivid colors and video capabilities while consuming no energy for static image storage. This technology addresses common issues such as poor readability in outdoor environments and high power consumption associated with traditional display methods. Bodle Technologies also offers zero-power reflective displays, bi-stable reflective displays with ultra-high resolution, smart windows, and security coatings that can change color through various probing techniques. These products provide enhanced security features for currencies, ID cards, and official documentation. Founded in 2015, Bodle Technologies is headquartered in Begbroke, United Kingdom.

GripAble Ltd. designs and develops digital therapy devices aimed at improving rehabilitation for individuals with movement impairments such as stroke, arthritis, cerebral palsy, and trauma. Founded in 2017 and based in London, the company offers a portable, wireless handgrip device that connects to a mobile application. This application allows users to engage with therapy games while providing assessment and training for hand and arm functions. GripAble's innovative approach focuses on making therapy more accessible and engaging for patients, enabling them to practice essential daily tasks in a fun and motivating way. By combining hardware and software, GripAble addresses the needs of over 500 million people worldwide who face challenges with arm mobility, facilitating self-training both in clinical settings and at home.

Ducentis BioTherapeutics Limited is a pre-clinical stage company based in Witney, United Kingdom, focused on developing novel therapies for inflammation and autoimmune diseases. Established in 2014, the company aims to modify a naturally occurring protein with significant immunoregulatory functions. Ducentis targets the CD200/CD200R axis, which delivers a deactivating signal to activated immune cells in both the innate and adaptive immune systems. Their potential therapeutic applications include addressing transplant rejection and treating various autoimmune and inflammatory diseases that affect the lungs, liver, kidneys, eyes, bones, and cartilage.

Curileum Discovery Ltd, based in London, is a biotechnology company focused on developing innovative therapeutic solutions for gastrointestinal diseases. Established in 2013, the company is engaged in discovering novel treatments to address early-stage severe gastrointestinal conditions. One of its key developments, ULI-015, is a small molecule designed to redirect the production of precancerous cells in polyps to healthy tissue. In preclinical studies using a porcine bowel cancer model, ULI-015 demonstrated significant efficacy, leading to a reduction in polyp numbers and promoting the fusion of regressed polyps with healthy tissue. Curileum has also established a large-scale method to extract ULI-015 from plant sources and is pursuing Orphan Drug Designation to initiate clinical testing in patients with familial adenomatous polyposis. Positioned at St Mark’s Hospital, which houses Europe’s largest registry of FAP patients, Curileum aims to address the sporadic bowel cancer market by targeting high-risk individuals identified through screening programs. The company is currently seeking funding to advance ULI-015 towards clinical proof of concept.

Glide Pharmaceutical Technologies is a clinical stage development company that specializes in the creation of solid dose formulations for therapeutics and vaccines. The company is known for its innovative solid dose injector system, which aims to enhance patient compliance in self-administering long-term therapies. Glide's product pipeline features formulations for various medications, including octreotide, teriparatide, and vaccines for anthrax and influenza. The company's focus on needle-free injection methods seeks to improve the treatment experience for both patients and healthcare providers. Formerly known as Caretek Medical, Glide Pharmaceutical is dedicated to advancing healthcare through its unique delivery systems.

OxSonics Therapeutics is a biotechnology company focused on improving anti-cancer therapies through its innovative SonoTran platform. This technology enhances the delivery of anti-cancer agents to solid tumors by disrupting their structure, thereby increasing efficacy and reducing toxicity without the need for drug reformulation. SonoTran operates by co-administering particles with anti-cancer drugs, creating a localized pumping effect that improves drug penetration within tumors. Designed to integrate seamlessly into existing oncology workflows, the platform also allows healthcare professionals to visualize treatment progress in real-time. Originating from research at the University of Oxford’s Institute of Biomedical Engineering, OxSonics is headquartered in Oxford, UK.

Electrowinning Technologies Ltd specializes in manufacturing power electronic equipment tailored for the metal industry, particularly focusing on copper production. Established in 2016 and based in Bristol, United Kingdom, the company offers innovative solutions such as in-suite copper concentration control for electrorefining, anodes equipped with integrated point-of-use power converters for electrowinning, and flow optimized cells for copper liberation. The technology developed by Electrowinning Technologies effectively manages the significant currents used in metal-winning operations, enhancing both the quality and quantity of produced metals while simultaneously reducing energy consumption. This technology is particularly relevant for electrorefining, which is the predominant copper refining method in Europe.

Curileum Discovery Ltd, based in London, is a biotechnology company focused on developing innovative therapeutic solutions for gastrointestinal diseases. Established in 2013, the company is engaged in discovering novel treatments to address early-stage severe gastrointestinal conditions. One of its key developments, ULI-015, is a small molecule designed to redirect the production of precancerous cells in polyps to healthy tissue. In preclinical studies using a porcine bowel cancer model, ULI-015 demonstrated significant efficacy, leading to a reduction in polyp numbers and promoting the fusion of regressed polyps with healthy tissue. Curileum has also established a large-scale method to extract ULI-015 from plant sources and is pursuing Orphan Drug Designation to initiate clinical testing in patients with familial adenomatous polyposis. Positioned at St Mark’s Hospital, which houses Europe’s largest registry of FAP patients, Curileum aims to address the sporadic bowel cancer market by targeting high-risk individuals identified through screening programs. The company is currently seeking funding to advance ULI-015 towards clinical proof of concept.

Lupe Technology Limited, founded in 2014 and based in Old Sodbury, United Kingdom, specializes in the development and manufacture of cordless vacuum cleaners. The company focuses on enhancing cordless vacuuming capabilities through its suction intensifier technology, which features a cyclonic system and HEPA filtration. Lupe's products are designed to provide powerful suction, incorporating a motorized agitator with a rotating seal that effectively cleans hair and deep-down dirt. Additionally, their vacuum cleaners are equipped with removable battery packs, allowing users to conveniently clean their homes without the restrictions of traditional corded devices.

Active Needle Technology Ltd. is a medical device start-up based in Abingdon, United Kingdom, founded in 2016. The company focuses on developing innovative needle actuating device technology that enhances precision in ultrasound-guided interventional procedures, including regional anesthesia and cancer biopsies. Its proprietary platform utilizes a hand-held, single-use piezoelectric device that induces minute longitudinal ultrasonic vibrations to improve the accuracy of needle placement. This technology aims to transform treatment pathways in interventional radiology by providing safer and more efficient methods for clinicians and healthcare providers, ultimately benefiting patients. Active Needle's advancements represent a significant improvement over existing technologies in the field.

Molecular Warehouse Ltd., incorporated in 2015 and based in Twickenham, United Kingdom, specializes in developing proteins for diagnostics and therapeutics. The company focuses on creating patient-centric biosensor technology that enhances molecular diagnostics. Their innovative electrochemical biosensors are designed to detect a variety of biomarkers with high specificity and sensitivity, allowing for rapid health monitoring. This technology enables patients to conduct regular health assessments from home and facilitates seamless communication of test results with healthcare providers through smart devices.

Ducentis BioTherapeutics Limited is a pre-clinical stage company based in Witney, United Kingdom, focused on developing novel therapies for inflammation and autoimmune diseases. Established in 2014, the company aims to modify a naturally occurring protein with significant immunoregulatory functions. Ducentis targets the CD200/CD200R axis, which delivers a deactivating signal to activated immune cells in both the innate and adaptive immune systems. Their potential therapeutic applications include addressing transplant rejection and treating various autoimmune and inflammatory diseases that affect the lungs, liver, kidneys, eyes, bones, and cartilage.

Orbit Discovery Ltd. is a biotechnology company specializing in peptide display technology to discover peptide drugs for chronic diseases. Established in 2015 and based in Oxford, United Kingdom, the company utilizes an innovative in vitro bead display platform that links randomized peptide sequences to their encoding DNA. This technology enables high-throughput screening of peptides, facilitating the identification and optimization of potential drug candidates. By combining the specificity and efficacy of large biologic molecules with the advantages of small molecules, such as lower manufacturing costs and simpler delivery methods, Orbit Discovery aims to address a wide range of chronic diseases affecting large patient populations. The company's focus is on both internal drug discovery programs and collaborative research efforts, streamlining the discovery process and accelerating the development of new peptide therapeutics.

Azellon Limited is a company based in London, United Kingdom, that specializes in the development and commercialization of a unique tissue repair technology utilizing mesenchymal stem cells combined with a biological scaffold. The company's primary product, Cell Bandage, is designed for the repair of avascular meniscal tears in the knee, addressing a significant issue in orthopedic treatment where surgeons often resort to partial or complete meniscus removal. This conventional approach can lead to osteoarthritic changes in the knee joint over time. Developed by Professor Anthony Hollander, Azellon's technology has demonstrated notable success in in-vitro models over a five-year research period. Established in 2007, Azellon Limited aims to offer a more effective solution for knee injuries that preserves the meniscus and promotes natural healing.

Lightpoint Medical, Ltd. is a medical device company based in Rickmansworth, United Kingdom, founded in 2012. The company specializes in developing innovative imaging technologies for cancer surgery, particularly through its Cerenkov Luminescence Imaging (CLI) technology. This breakthrough intraoperative imaging tool allows for real-time detection of cancer during surgical procedures, which can significantly reduce the chances of cancer recurrence and the necessity for reoperations. By optimizing the performance of robotic cancer surgery, Lightpoint Medical aims to provide healthcare professionals with advanced tools that enhance surgical decision-making and improve patient outcomes, ultimately contributing to cost savings within the healthcare system.

Sime Diagnostics Ltd is a clinical AI platform company that specializes in neonatal healthcare, offering innovative solutions to improve patient outcomes in critical care settings. Founded in 2014 and based in London, the company has developed a proprietary software that provides data-driven insights to healthcare professionals, particularly in the neonatal intensive care unit. Their flagship product, the Lung Maturity Test (LMT), predicts Respiratory Distress Syndrome (RDS) in premature infants, allowing for timely interventions that can significantly reduce morbidity and mortality rates. The platform not only aids in real-time disease detection but also curates unique datasets for biomarker discovery, which can benefit both the company and its commercial partners across various medical fields. With a commitment to preventative, personalized medicine, Sime Diagnostics aims to enhance the quality of care through its advanced AI technologies.

Sasets.com offers a cloud-based project and asset management software platform tailored specifically for the construction and civil engineering industries. Built on Microsoft Azure, the platform enhances operational efficiency by replacing outdated paperwork with a mobile logistics solution that facilitates real-time data access. This enables users to track and manage all job-related documents, drawings, forms, and photos from project inception to completion. By automating processes and improving health and safety compliance, Sasets.com helps clients save time and reduce costs. The solution leverages vertical SaaS capabilities, which have been proven to deliver significant performance gains in similar sectors by streamlining workflows and enhancing employee productivity.

Message Missile, founded in 2013 by Thomas Young, specializes in location-based marketing solutions that enhance customer relationships and loyalty for brands. The company develops mobile phone software that utilizes global positioning system (GPS) technology and geofences to deliver location-specific information. This enables clients to send push notifications to users based on their current locations, thereby improving engagement and marketing effectiveness. Message Missile has partnered with some of the largest brands, demonstrating its capability in delivering innovative marketing strategies that leverage real-time location data.

Designer Carbon Materials Ltd specializes in the development of advanced nanomaterials, focusing on endohedral metallofullerenes for various applications such as energy harvesting, bio-sensing, and quantum nanoelectronics. The company emerged as a spin-out from the University of Oxford, building on over 12 years of research led by Dr. Kyriakos Porfyrakis and his team. They have successfully synthesized and chemically functionalized endohedral fullerenes, creating materials with tailored electronic properties. This innovative approach allows clients to utilize a range of nanostructures, including nanotubes and their derivatives, in both scientific and industrial applications.

Abgentis Limited is a biotechnology company based in Abingdon, United Kingdom, focused on developing intravenous and oral antibacterial products aimed at treating acute and chronic life-threatening infections, particularly those caused by drug-resistant bacteria. Established in 2012, the company specializes in the re-engineering of previously marketed antibacterials by applying advanced insights into the structure-activity relationships, microbiology, and pharmacology of antibacterial DNA supercoiling inhibitors. Through its innovative approach, Abgentis seeks to enhance the efficacy of existing treatments, thereby improving patient outcomes for those facing serious bacterial infections.

Run3D Limited operates clinics that specialize in musculoskeletal assessments to help individuals address persistent injuries. Founded in 2012 and based in Witney, United Kingdom, the company utilizes advanced three-dimensional gait analysis technology to evaluate biomechanics related to running injuries, performance issues, and footwear selection. Services are offered at various locations in the United Kingdom and Dublin, Ireland. Run3D employs a state-of-the-art motion capture system and draws on the world's largest biomechanical database to provide precise evaluations. The company aims to identify the root causes of injuries and develop personalized rehabilitation programs based on scientific measurements of gait, muscular strength, flexibility, and alignment. Collaborating with leading institutions such as the Running Injury Clinic at the University of Calgary, Run3D emphasizes an evidence-based approach to treating musculoskeletal overuse injuries.

Power OLEDs Ltd, based in the United Kingdom, specializes in the development and manufacturing of advanced materials for organic light-emitting diode (OLED) technology. This emerging display technology is recognized for its efficiency, enhanced performance, and environmental benefits compared to traditional LED, LCD, and plasma displays. Power OLEDs produces a range of critical components, including hole transporters, electron transporters, electron injectors, hosts, and emitters, aimed at improving the performance and durability of OLED products. With a team that boasts over 60 years of combined experience in the OLED sector, the company holds a significant intellectual property portfolio and maintains a robust pipeline of innovative materials. In 2019, Power OLEDs secured a licensing agreement with a Japanese manufacturer, further establishing its presence in the global market.

Combat Medical SL, based in Ajalvir, Spain, specializes in a novel treatment for superficial bladder cancer that enhances the efficacy of standard chemotherapy through a chemo-hyperthermia delivery system. This innovative approach involves heating chemotherapy agents and circulating them within the bladder, significantly reducing the recurrence rate of cancer to less than 20%, compared to the traditional treatment, which has a recurrence rate of 78% and often necessitates multiple surgeries. By improving treatment outcomes and minimizing the need for further surgical interventions, Combat Medical's solution not only offers clinical benefits but also presents substantial cost savings. The company is planning to expand its operations into the UK market.

Message Missile, founded in 2013 by Thomas Young, specializes in location-based marketing solutions that enhance customer relationships and loyalty for brands. The company develops mobile phone software that utilizes global positioning system (GPS) technology and geofences to deliver location-specific information. This enables clients to send push notifications to users based on their current locations, thereby improving engagement and marketing effectiveness. Message Missile has partnered with some of the largest brands, demonstrating its capability in delivering innovative marketing strategies that leverage real-time location data.

Metal Powders & Process is seeking to build an atomiser that will produce metal powders is high volumes, with no impurities. The hope is that this will allow more industries to begin using metal powders to craft their components. Currently, contaminants in metal powders cause weak points in components, which are negligible for most purposes, but unusable under high stress in environments such as Aerospace.

Lightpoint Medical, Ltd. is a medical device company based in Rickmansworth, United Kingdom, founded in 2012. The company specializes in developing innovative imaging technologies for cancer surgery, particularly through its Cerenkov Luminescence Imaging (CLI) technology. This breakthrough intraoperative imaging tool allows for real-time detection of cancer during surgical procedures, which can significantly reduce the chances of cancer recurrence and the necessity for reoperations. By optimizing the performance of robotic cancer surgery, Lightpoint Medical aims to provide healthcare professionals with advanced tools that enhance surgical decision-making and improve patient outcomes, ultimately contributing to cost savings within the healthcare system.

MicroVisk Limited, founded in 2004 and based in Oxford, United Kingdom, specializes in the development of innovative medical devices. The company has created CoagMax, a point-of-care monitor that enables patients to conduct PT/INR testing at home, facilitating self-monitoring of blood coagulation levels. This device utilizes advanced micro electro mechanical sensors embedded in a disposable smart strip, allowing for a convenient, safe, and accurate testing experience. By focusing on patient-friendly solutions, MicroVisk aims to improve the quality of life for individuals requiring regular blood coagulation monitoring.

Ibexis Technologies is a prominent provider of innovative sensory networking, remote data acquisition, monitoring, and control solutions tailored for various industries, including Environmental, Building and Construction, Energy, and Industrial sectors. The company’s offerings enable clients to enhance customer satisfaction, reduce operational costs, improve workplace health and safety, lower carbon footprints, and ensure regulatory compliance. Ibexis Technologies supports a range of industry-specific protocols, allowing for the remote monitoring and control of industrial equipment such as HMIs and PLCs, sensors, and supervisory systems. Their open systems approach facilitates seamless integration into existing customer environments while enhancing the capabilities of on-site systems. Users can securely access, control, and monitor these systems via laptops or smart devices, receiving timely alerts and warnings. The company’s diverse product and service portfolio includes the IM SERIES Hardware and Systems, an Enterprise Monitoring Software Suite, Managed Services, System Integration Services, and expertise in hardware and software product development.

Message Missile, founded in 2013 by Thomas Young, specializes in location-based marketing solutions that enhance customer relationships and loyalty for brands. The company develops mobile phone software that utilizes global positioning system (GPS) technology and geofences to deliver location-specific information. This enables clients to send push notifications to users based on their current locations, thereby improving engagement and marketing effectiveness. Message Missile has partnered with some of the largest brands, demonstrating its capability in delivering innovative marketing strategies that leverage real-time location data.

Combat Medical SL, based in Ajalvir, Spain, specializes in a novel treatment for superficial bladder cancer that enhances the efficacy of standard chemotherapy through a chemo-hyperthermia delivery system. This innovative approach involves heating chemotherapy agents and circulating them within the bladder, significantly reducing the recurrence rate of cancer to less than 20%, compared to the traditional treatment, which has a recurrence rate of 78% and often necessitates multiple surgeries. By improving treatment outcomes and minimizing the need for further surgical interventions, Combat Medical's solution not only offers clinical benefits but also presents substantial cost savings. The company is planning to expand its operations into the UK market.

BioMoti Limited is a London-based company focused on developing innovative cancer therapeutics designed to improve treatment efficacy while minimizing side effects. Established in 2009, the company has created a unique platform featuring Oncojans, a new class of therapeutic microparticles that can effectively target and penetrate cancer cells. These microparticles facilitate the slow release of drugs directly at the site of need, thereby sparing healthy tissue from the damaging effects commonly associated with traditional chemotherapy. Among its notable products is MOTI1001, an Oncojan-based candidate for ovarian cancer, which has shown promising results in early preclinical studies. By employing this targeted delivery approach, BioMoti aims to revolutionize cancer treatment and address significant challenges in current therapeutic practices.

Run3D Limited operates clinics that specialize in musculoskeletal assessments to help individuals address persistent injuries. Founded in 2012 and based in Witney, United Kingdom, the company utilizes advanced three-dimensional gait analysis technology to evaluate biomechanics related to running injuries, performance issues, and footwear selection. Services are offered at various locations in the United Kingdom and Dublin, Ireland. Run3D employs a state-of-the-art motion capture system and draws on the world's largest biomechanical database to provide precise evaluations. The company aims to identify the root causes of injuries and develop personalized rehabilitation programs based on scientific measurements of gait, muscular strength, flexibility, and alignment. Collaborating with leading institutions such as the Running Injury Clinic at the University of Calgary, Run3D emphasizes an evidence-based approach to treating musculoskeletal overuse injuries.

Acunu Analytics specializes in providing a platform for low-latency, continuous analytics on big data, enabling real-time insights across various industries such as manufacturing, telecommunications, media, and financial services. The company's offerings include dashboards and embedded applications designed for monitoring and controlling complex environments where high-velocity data is prevalent. Central to Acunu's technology is the Cassandra NoSQL database, and the company actively contributes to its development by sharing innovations with the wider community. Founded in 2009 by a team of researchers and engineers from Cambridge and Oxford, Acunu operates offices in London and California, and is supported by prominent venture capital firms in Europe.

Azellon Limited is a company based in London, United Kingdom, that specializes in the development and commercialization of a unique tissue repair technology utilizing mesenchymal stem cells combined with a biological scaffold. The company's primary product, Cell Bandage, is designed for the repair of avascular meniscal tears in the knee, addressing a significant issue in orthopedic treatment where surgeons often resort to partial or complete meniscus removal. This conventional approach can lead to osteoarthritic changes in the knee joint over time. Developed by Professor Anthony Hollander, Azellon's technology has demonstrated notable success in in-vitro models over a five-year research period. Established in 2007, Azellon Limited aims to offer a more effective solution for knee injuries that preserves the meniscus and promotes natural healing.

Select Technology is a design and engineering company, provides software solutions for the copier and multi-function device industry. It offers PaperCut MF, a print, copy, fax, and scan management solution; KPAX Manage, a print fleet management solution for resellers; Presto, which enables users to publish existing Windows print queues to iOS device; EveryonePrint, a mobile print solution; Drivve Image, a scanning software; and selectSCAN, a scanning and capture solution for employees.

Orthogem Limited specializes in developing and manufacturing synthetic bone grafts, utilizing its patented Tripore technology platform. This innovative platform has led to a diverse range of synthetic bone grafts (SBGs) designed for various clinical applications, including spinal and oral craniofacial surgeries. Orthogem's product offerings include TriPore Granules, TriPore MPA, and TriPore Blocks. Established in 2001 and headquartered in Nottingham, United Kingdom, the company focuses on achieving optimal bone remodeling through the osteoconductive and bioactive properties of its materials. These grafts are applicable for treating a wide array of conditions, including fractures, congenital disorders, traumatic injuries, and bone cancer, thereby providing reliable solutions for patients undergoing procedures such as lumbar spine fusion.

MicroVisk Limited, founded in 2004 and based in Oxford, United Kingdom, specializes in the development of innovative medical devices. The company has created CoagMax, a point-of-care monitor that enables patients to conduct PT/INR testing at home, facilitating self-monitoring of blood coagulation levels. This device utilizes advanced micro electro mechanical sensors embedded in a disposable smart strip, allowing for a convenient, safe, and accurate testing experience. By focusing on patient-friendly solutions, MicroVisk aims to improve the quality of life for individuals requiring regular blood coagulation monitoring.

Crysalin Limited, founded in June 2007 in London, focuses on the research and development of crysalin lattice technology, which originated from patented work at Oxford University. The company specializes in crysalins, a protein-based nanotechnology that significantly enhances protein structure determination, particularly for challenging macromolecular targets such as membrane proteins and flexible soluble proteins. By imposing order on these targets, crysalins enable advanced imaging techniques like X-ray crystallography and electron microscopy to resolve three-dimensional molecular structures that other methods cannot. In addition to protein structure determination, Crysalin's technology holds promise for applications in biosensor development and optoelectronics, positioning the company as a key player in the field of biophysical research and nanotechnology.

Acunu Analytics specializes in providing a platform for low-latency, continuous analytics on big data, enabling real-time insights across various industries such as manufacturing, telecommunications, media, and financial services. The company's offerings include dashboards and embedded applications designed for monitoring and controlling complex environments where high-velocity data is prevalent. Central to Acunu's technology is the Cassandra NoSQL database, and the company actively contributes to its development by sharing innovations with the wider community. Founded in 2009 by a team of researchers and engineers from Cambridge and Oxford, Acunu operates offices in London and California, and is supported by prominent venture capital firms in Europe.

MicroVisk Limited, founded in 2004 and based in Oxford, United Kingdom, specializes in the development of innovative medical devices. The company has created CoagMax, a point-of-care monitor that enables patients to conduct PT/INR testing at home, facilitating self-monitoring of blood coagulation levels. This device utilizes advanced micro electro mechanical sensors embedded in a disposable smart strip, allowing for a convenient, safe, and accurate testing experience. By focusing on patient-friendly solutions, MicroVisk aims to improve the quality of life for individuals requiring regular blood coagulation monitoring.

LabMinds Limited specializes in automating solution preparation for liquid-handling laboratories across the globe, particularly in the pharmaceutical and life sciences sectors. Founded in 2009 and headquartered in Oxford, United Kingdom, with an additional office in Somerville, Massachusetts, the company offers The Revo solution preparation system. This innovative platform combines artificial intelligence and robotics to streamline the drug development process, addressing the challenges of manual operations that often lead to errors and waste. By connecting its system to a cloud-based platform, LabMinds enables remote access and facilitates the collection of input and sensor data, providing valuable insights into chemical interactions. The company aims to enhance laboratory accuracy and control while accelerating the development of meaningful therapies, thereby supporting scientists and businesses in optimizing their operations.

Glide Pharmaceutical Technologies is a clinical stage development company that specializes in the creation of solid dose formulations for therapeutics and vaccines. The company is known for its innovative solid dose injector system, which aims to enhance patient compliance in self-administering long-term therapies. Glide's product pipeline features formulations for various medications, including octreotide, teriparatide, and vaccines for anthrax and influenza. The company's focus on needle-free injection methods seeks to improve the treatment experience for both patients and healthcare providers. Formerly known as Caretek Medical, Glide Pharmaceutical is dedicated to advancing healthcare through its unique delivery systems.

Base4 specializes in the innovation and development of advanced technologies for single-molecule analysis, specifically focusing on microdroplet-based sequencing. This technology facilitates pathogen screening and DNA analysis by generating long reads from individual DNA molecules without requiring initial amplification. As a result, Base4's solutions enable users to better understand and predict diseases while providing cost-effective and accurate sequencing data for large populations. The company is committed to building a valuable portfolio of intellectual property and technical expertise that underpins its innovative offerings.

MicroVisk Limited, founded in 2004 and based in Oxford, United Kingdom, specializes in the development of innovative medical devices. The company has created CoagMax, a point-of-care monitor that enables patients to conduct PT/INR testing at home, facilitating self-monitoring of blood coagulation levels. This device utilizes advanced micro electro mechanical sensors embedded in a disposable smart strip, allowing for a convenient, safe, and accurate testing experience. By focusing on patient-friendly solutions, MicroVisk aims to improve the quality of life for individuals requiring regular blood coagulation monitoring.

Diamond Microwave Devices Ltd. specializes in the development of semiconductor devices utilizing chemical vapor deposition (CVD) diamond technology. Founded in 2006 and headquartered in Leeds, United Kingdom, the company focuses on creating devices that serve both civil and defense sectors, specifically for microwave power amplifier and transmitter applications. As a subsidiary of Element Six (Pty) Ltd., Diamond Microwave Devices aims to advance the performance and efficiency of microwave technologies through innovative diamond-based solutions.

Acunu Analytics specializes in providing a platform for low-latency, continuous analytics on big data, enabling real-time insights across various industries such as manufacturing, telecommunications, media, and financial services. The company's offerings include dashboards and embedded applications designed for monitoring and controlling complex environments where high-velocity data is prevalent. Central to Acunu's technology is the Cassandra NoSQL database, and the company actively contributes to its development by sharing innovations with the wider community. Founded in 2009 by a team of researchers and engineers from Cambridge and Oxford, Acunu operates offices in London and California, and is supported by prominent venture capital firms in Europe.

Azellon Limited is a company based in London, United Kingdom, that specializes in the development and commercialization of a unique tissue repair technology utilizing mesenchymal stem cells combined with a biological scaffold. The company's primary product, Cell Bandage, is designed for the repair of avascular meniscal tears in the knee, addressing a significant issue in orthopedic treatment where surgeons often resort to partial or complete meniscus removal. This conventional approach can lead to osteoarthritic changes in the knee joint over time. Developed by Professor Anthony Hollander, Azellon's technology has demonstrated notable success in in-vitro models over a five-year research period. Established in 2007, Azellon Limited aims to offer a more effective solution for knee injuries that preserves the meniscus and promotes natural healing.

Warwick Effect Polymers Limited manufactures and markets complex polymers using living controlled radical polymerization.

OrganOx Limited, founded in 2008 and based in Oxford, United Kingdom, specializes in organ preservation and transplantation technology, particularly for liver transplants. The company has developed the Metra device, which employs normothermic preservation technology to store livers outside the body at normal body temperature. This innovative approach mimics the conditions of the human body by continuously perfusing the liver with oxygen-carrying red cells and nutrients, thereby preventing the decay of the organ before transplantation. The Metra device enables the liver to produce bile, metabolize glucose, and maintain a physiological pH level, ultimately enhancing the viability of the organ for transplant. OrganOx's research and development efforts are rooted in the work of Prof Peter Friend and Prof Constantin Coussios at the University of Oxford.

Mirriad Advertising PLC operates an in-content advertising platform that leverages artificial intelligence and computer vision technology to dynamically insert products and innovative signage into video content post-production. This method allows advertisers to integrate their offerings seamlessly into existing media, enhancing viewer engagement without interrupting the viewing experience. Mirriad's technology creates new advertising inventory, providing additional revenue opportunities for content producers and distributors while improving overall viewer satisfaction by minimizing commercial interruptions. The company primarily generates revenue from the United States and has a presence in Europe and China.

Agilent Raman Spectroscopy’s proprietary technologies use novel variants of Raman spectroscopy. Their instruments can rapidly and accurately identify materials hidden inside objects or through opaque barriers such as plastic, coloured glass, paper and skin, or can measure the concentrations of materials in mixtures, with a high degree of accuracy. Agilent Raman Spectroscopy is formerly known as Cobalt Light Systems and is part of Agilent.

Meciria develops an oil well drilling tool for the oil industry.

Glide Pharmaceutical Technologies is a clinical stage development company that specializes in the creation of solid dose formulations for therapeutics and vaccines. The company is known for its innovative solid dose injector system, which aims to enhance patient compliance in self-administering long-term therapies. Glide's product pipeline features formulations for various medications, including octreotide, teriparatide, and vaccines for anthrax and influenza. The company's focus on needle-free injection methods seeks to improve the treatment experience for both patients and healthcare providers. Formerly known as Caretek Medical, Glide Pharmaceutical is dedicated to advancing healthcare through its unique delivery systems.

Novacta Biosystems Ltd, founded in 2003, specializes in the development of biopharmaceuticals aimed at treating bacterial infections, particularly those caused by drug-resistant strains. The company employs a dual business model that combines biocatalysis and microbial pathway engineering services with the discovery and development of novel small peptide molecules known as lantibiotics. These innovative therapies target various bacterial infections, including Clostridium difficile. By leveraging the expertise of GSK's Biotransformation and Natural Products scientific team, Novacta has established a robust infectious disease therapeutic pipeline, focusing on delivering effective anti-infective solutions.

Arecor Limited is a biopharmaceutical company based in Cambridge, United Kingdom, specializing in stabilization technology solutions for the pharmaceutical and biotech sectors. Founded in 2006, Arecor utilizes its innovative formulation technology platform to enhance the commercial value and utility of proteins across various applications, including vaccines and therapeutic proteins. The company develops products targeting infectious diseases, diabetes, oncology, immunology, and hormone replacement therapies. It focuses on reformulating existing therapies to improve their stability and efficacy, enabling self-administration for patients through pre-filled syringes and injection pens. Notably, Arecor works on high-concentration formulations of antibodies, such as Trastuzumab and Rituximab, to improve treatment for conditions like breast cancer and non-Hodgkin’s lymphoma. Additionally, Arecor creates stable liquid formulations for vaccines and biological therapies, addressing challenges in degradation and stability. Through partnerships with leading pharmaceutical companies, Arecor aims to deliver advanced reformulations that enhance treatment options for patients.

Pharma Engineering has developed and patented a gentle method to remove tablets and capsules from blister packs without damaging them. The pharmaceutical industry is large and manufactures billions of blister-packaged tablets. It is common for 2-6% of this manufactured product to be stopped for quality reasons relating to the packaging. Recovering these tablets so that they can be re-packaged can yield easy savings.

Oxtox is developing Drugsensorâ„¢, a device that uses novel and cost-effective technology to rapidly detect whether a person is currently 'under the influence' of specific drugs, all with a minimum of inconvenience.

Incentec Ltd has been developing a predictive diagnostic for pre-eclampsia, a poorly defined condition affecting approximately 6% of first pregnancies. The causes of pre-eclampsia are unknown, although a failure in placental development is thought to be a factor. There is no diagnostic test currently in use and at the moment, at-risk patients (or suspected cases of pre-eclampsia) are monitored and treated on the basis of observable and developing clinical symptoms.

Imagineer Systems Limited specializes in developing visual effects solutions for the film, video, and broadcast post-production industries. Founded in 2000 and based in Guildford, United Kingdom, the company produces a range of software tools designed to enhance visual content. Its notable products include Monet, a comprehensive tracking and compositing toolset, and Mokey, which facilitates the removal of unwanted elements such as wires and logos from footage. Additionally, Imagineer Systems offers Mocha, a robust 2D tracking and rotoscoping tool that provides precise motion tracking essential for special effects. The company also delivers various additional services, including virtual product placement, lens distortion correction, noise reduction, grain management, and keying tools, catering to the diverse needs of commercial and film video post-production.

Dexela develops advanced 3-D breast imaging technology aimed at the early detection of breast cancer. The company offers a range of products, including the DexTop Digital Mammography Workstation, which streamlines screening workflow and performance, and a 3D reconstruction engine available to OEM partners as a software module. Dexela's flat panel CMOS X-ray detectors serve various medical applications, such as mammography, breast CT, dental imaging, and fluoroscopy. Additionally, the company provides consulting services in digital tomosynthesis, mammography acquisition geometry, and the optimal reconstruction of 3D data. Founded in 2003 and headquartered in London, Dexela also operates an X-ray research and development facility in Sudbury, Massachusetts.

Usentric develops online proxy solution for brands in the retail, financial services and telecommunication industries. The company's products and services include secure payment online solutions, email protection, and secure ID. It is based in Sutton, U.K.

Naked Objects Group provides Java-based application development platforms.

Glide Pharmaceutical Technologies is a clinical stage development company that specializes in the creation of solid dose formulations for therapeutics and vaccines. The company is known for its innovative solid dose injector system, which aims to enhance patient compliance in self-administering long-term therapies. Glide's product pipeline features formulations for various medications, including octreotide, teriparatide, and vaccines for anthrax and influenza. The company's focus on needle-free injection methods seeks to improve the treatment experience for both patients and healthcare providers. Formerly known as Caretek Medical, Glide Pharmaceutical is dedicated to advancing healthcare through its unique delivery systems.

Inspiration Matters has developed a software and hardware system to drive high quality displays such as those used in car dealerships, estate agents and banks.

Impact Applications Ltd. specializes in designing, developing, and supporting enterprise software applications tailored for various industries. The company offers a range of products, including impactRESPONSE, which serves the repairs and maintenance needs of social housing and insurance reinstatement; impactUNWIRED, a wireless barcode scanning application for component distribution; impactCONNECT, a platform for bulk SMS and voice messaging; and impactCOMMERCE, an integrated e-commerce solution. In addition to its software offerings, the company provides consultancy and support services, such as maintenance contracts and helpdesk assistance. Founded in 2000, Impact Applications Ltd. is headquartered in Wolverhampton, United Kingdom, and operates as a subsidiary of Castleton Technology plc.

Wright Fenn provides medicine pills are manufactured and packaged in blister packs. For many patients, such as those in residential or care homes, hospitals or other institutions, these pills are repackaged by the pharmacy into dosage specific monthly packs to save nursing time and reduce dosage errors. Pharmaceutical licenses typically specify the form of the packaging and so it is expensive for the manufacturers to make and package pills in bulk form for pharmacies to repackage them into dosage specific packs. During 2003, pharmacists in the UK alone deblistered and repackaged approximately 70 million packs of pills ' mostly by hand. The number of patients requiring these patient specific packs is increasing each year at about 10-15%.

Kinomi provides a better way of automatically archiving and indexing email, both by subject matter, sender and receiver groups, and by reading content, which then enables people and organisations to retrieve relevant emails much more easily, if ever they are needed at some point in the future.

BioAnaLab Ltd. is a services provider that specializes in the analysis of biologic drugs and vaccines. BioAnaLab was spun out of the University of Oxford in 2002 to meet the unique requirements of the biopharmaceutical industry. The Company helps its customers better understand the safety and efficacy of biologic drugs and vaccines by providing a broad range of services to assist with evaluating and advancing these therapeutics from the drug development pipeline to the market

Water Innovate focuses on bridging the gap between research and industry innovation in the water and environmental sectors. The company specializes in the development and commercialization of advanced water and wastewater treatment technologies. By evaluating new technologies and investing resources in their development, Water Innovate effectively identifies routes to market. Their portfolio includes a variety of cutting-edge products designed by leading experts in the field, aimed at addressing the challenges faced by the water industry. These technologies are systematically transferred from research laboratories to the marketplace, facilitating practical solutions for the international water and environmental sectors.

Scancell is focused on developing innovative therapeutic vaccines aimed at treating cancer and infectious diseases, leveraging its proprietary technology platforms, ImmunoBody and Moditope. The company is advancing its lead cancer vaccine, SCIB1, which targets melanoma and is currently in Phase 1/2 clinical trials. Preliminary data from these trials indicated that SCIB1 may elicit an immune response potentially linked to clinical benefits for patients with malignant melanoma. Scancell's ImmunoBody platform is designed to generate strong T cell responses that specifically target and eliminate tumor cells, while the Moditope technology addresses immune suppression caused by tumors, enabling activated T cells to effectively attack otherwise concealed cancer cells.

Warwick Effect Polymers Limited manufactures and markets complex polymers using living controlled radical polymerization.

Inscentinel uses the exquisitely sensitive olfactory sense of bees to detect minute concentrations of volatile compounds such as explosives, drugs, or odours that indicate disease. The bees are held in a harness and can then be trained to recognize particular scents, in much the same way that sniffer dogs can be trained. In the presence of the odour for which they have been trained, the bees have a proboscis extension reflex, and this is then picked up by a camera and its associated software that then sends a signal to an operator or simply logs the data. A US patent has been granted and other patent applications are proceeding.

Caretek Medical has developed a needle-free injection technology. The system comprises a hand-held spring-powered reusable actuator plus a single-use disposable cassette which houses a splinter of drug in solid form. In use, the cassette is engaged with the actuator and then pressed against the skin. This pressure further charges an internal spring and, at the critical point, the internal components are brought into alignment, releasing the spring which then causes the drug splinter to be pushed to a controlled and repeatable depth within the skin. The basic idea is covered by a number of patent applications which have recently started to grant.

Diamond Hard Surfaces Ltd. is a materials technology company based in Towcester, United Kingdom, established in 2004. The company specializes in producing Adamant, an amorphous diamond-like carbon coating that enhances the performance of various substrates, including steel and thermoplastics. These coatings are designed to improve durability by reducing friction, enhancing wear resistance, and providing superior load-carrying capabilities. Diamond Hard Surfaces employs a patented process that allows for the application of thicker layers at lower temperatures, making the coatings suitable for demanding environments such as aerospace, defense, oil and gas, medical, motorsport, and process plants. The unique characteristics of the Adamant coatings, including their low coefficient of friction and excellent resistance to chemical corrosion, make them ideal for extending the life and performance of components in challenging conditions.

Novacta Biosystems Ltd, founded in 2003, specializes in the development of biopharmaceuticals aimed at treating bacterial infections, particularly those caused by drug-resistant strains. The company employs a dual business model that combines biocatalysis and microbial pathway engineering services with the discovery and development of novel small peptide molecules known as lantibiotics. These innovative therapies target various bacterial infections, including Clostridium difficile. By leveraging the expertise of GSK's Biotransformation and Natural Products scientific team, Novacta has established a robust infectious disease therapeutic pipeline, focusing on delivering effective anti-infective solutions.

Scancell is focused on developing innovative therapeutic vaccines aimed at treating cancer and infectious diseases, leveraging its proprietary technology platforms, ImmunoBody and Moditope. The company is advancing its lead cancer vaccine, SCIB1, which targets melanoma and is currently in Phase 1/2 clinical trials. Preliminary data from these trials indicated that SCIB1 may elicit an immune response potentially linked to clinical benefits for patients with malignant melanoma. Scancell's ImmunoBody platform is designed to generate strong T cell responses that specifically target and eliminate tumor cells, while the Moditope technology addresses immune suppression caused by tumors, enabling activated T cells to effectively attack otherwise concealed cancer cells.

Hardide Coatings is a UK-based company specializing in tungsten carbide coatings designed to enhance the durability of metal components in harsh environments. Utilizing a patented low-temperature chemical vapor deposition process, the coatings provide significant wear and corrosion resistance while maintaining toughness and ductility. This technology extends the lifespan of critical components across various high-value industries, including oil and gas, aerospace, petrochemical, power generation, defense, and industrial tooling. Hardide operates in multiple regions, including the UK and the United States, and focuses on delivering advanced solutions for applications that require robust performance in abrasive, erosive, and chemically aggressive conditions.

Invro Limited is an electronic engineering company based in Bristol, United Kingdom, established in 2003. The company specializes in the efficient management of electrical energy through various electronic solutions. Its product offerings include single earpiece radios, radio receiver sets, and FM radios. Additionally, Invro provides high voltage power supplies tailored for scientific and industrial applications, as well as instrumentation designed for power electronics. The company's focus on developing advanced energy technologies supports the needs of industrial and scientific businesses, enabling them to access efficient energy management devices and reliable power supply modules.

Caretek Medical has developed a needle-free injection technology. The system comprises a hand-held spring-powered reusable actuator plus a single-use disposable cassette which houses a splinter of drug in solid form. In use, the cassette is engaged with the actuator and then pressed against the skin. This pressure further charges an internal spring and, at the critical point, the internal components are brought into alignment, releasing the spring which then causes the drug splinter to be pushed to a controlled and repeatable depth within the skin. The basic idea is covered by a number of patent applications which have recently started to grant.

Telegesis specializes in wireless mesh networking modules that utilize Silicon Labs' technology. The company has developed a communications protocol designed to transmit small amounts of data over extended distances while minimizing power consumption. Telegesis's products enable communication between devices located up to one kilometer apart. These devices are capable of self-configuring into a mesh network, allowing data to efficiently hop from node to node, thereby enhancing connectivity and reliability in various applications.

Ciphergrid Ltd (previously Cipherware Ltd) has developed what it believes is a unique data access technology that, in its simplest form, enables enterprise applications (e.g. ERP, CRM, or stand alone applications such as MS Excel) to perform transactions with multiple, disparate, remote databases across the Internet in the same way (speed, functionality, security) as if the databases were local. Ciphergrid's uniqueness lies in the fact that it offers a reliably high transactional speed, that it is a 'plug & play' solution and that it offers significantly lower total cost of ownership than any alternative. Its built-in data encryption and security control mechanisms allow the use of the Internet instead of expensive, non scaleable, leased lines.

ReviveR Technologies Limited, (formerly known as PC Help Centre) is a UK based research and development company, which specialises in designing intelligent remote diagnostic tools for use within mission-critical PCs, servers and manufacturing control equipment. Today, ReviveR Technologies offer affordable diagnostic tools that provide advanced, yet simplified secure remote access, monitor and control management for mission-critical equipment 24/7/365. The essence of the technology is that a board or chip resides in a PC or server and reports back over the internet on the detailed status of the PC. If a fault develops, the fault is reported. If it cant be corrected remotely as is often possible with software faults, then an engineer is able to arrive with the necessary hardware module so that the fault may be fixed at a single visit.